Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma...

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Infectious Diseases

Background:

• Vancomycin area under the curve/minimum inhibitory concentration (AUC/MIC) is a proposed therapeutic drug monitoring (TDM) target.
• Traditional AUC estimation is time-consuming; a two-point trough-peak method offers a simpler alternative.
• The two-point AUC/MIC method and target have not been validated in Chinese patients.

Purpose of the Study:

• To compare clinical outcomes of vancomycin therapy in Chinese older adults (>60 years).
• To evaluate trough-only versus two-point peak-trough AUC TDM approaches for vancomycin dosing.

Main Methods:

• Patients were divided into study (two-point TDM, target AUC/MIC ≥ 400) and control (trough-based TDM, target trough 15-20 mg/L) groups.
• Vancomycin effectiveness assessed via clinical findings, lab values, and bacteriologic response.
• Treatment effects and kidney function compared between groups.

Main Results:

• 200 patients included: 80 in the study group, 120 in the control group. Average age was 69.8 years.
• Staphylococcus aureus was the most common pathogen (34%).
• Excellent vancomycin response rates were significantly higher in the study group (90%) vs. control group (73.3%), P=0.0039. No vancomycin-related nephrotoxicity observed.

Conclusions:

• The two-point peak-trough method is a practical approach for vancomycin AUC estimation.
• An AUC/MIC ≥ 400 target is effective and safe for vancomycin therapy in older Chinese patients.